BRIEF—Minerva Biotechnologies to kick off CAR-T trials

Minerva Biotechnologies has announced it has been approved to start clinical trials of a CAR-T cell therapy for solid tumors, dubbed huMNC2-CAR44.

Minerva intends to commence clinical trials in breast cancer before the end of 2019.

Chief executive Cynthia Bamdad said: “We are delighted that we will soon be able to begin human clinical trials for metastatic breast cancer. Over 95% of breast cancers are positive for MUC1, and this cancer immunotherapy has the potential to bring hope to the many thousands of patients battling this terrible disease.”